Barclays Lifts Hims & Hers Target on Novo-Nordisk Deal Clearing Legal Hurdles
The optimism in healthcare stocks shifted this week as Barclays raised its price target on Hims & Hers Health (HIMS), arguing the company can accelerate growth now that a major legal overhang tied to a Novo Nordisk distribution agreement has been resolved. The move came as part of a broader reassessment of the GLP-1 landscape and its impact on specialty care players.
In a note issued to clients, Barclays analyst Glen Santangelo reiterated an Overweight stance on Hims & Hers but nudged the target higher to $29 from $25. He attributed the upgrade to the Novo Nordisk deal clearing a material legal cloud, enabling management to pursue accelerated market access and scaled partnerships without the prior risk of litigation derailing plans.
Santangelo argued that the resolution of the overhang should translate into clearer visibility on growth trajectories and cash generation, particularly as Hims & Hers continues to expand its subscriber base and broaden its service mix. “With the cloud lifted, the company can focus on executing its distribution strategies and expanding product lines,” he said in the update. The target lift, he added, reflects confidence in a pathway to higher user engagement and stable cash flow over the next two years.
The upgrade also dovetails with a sector outlook that has grown more favorable in light of regulatory and competitive dynamics around GLP-1 therapies. While the broader market remains attentive to affordability pressures and payer constraints, Barclays argues that Hims & Hers is poised to capture incremental demand through a mix of telehealth access, digital therapeutics, and consumer-brand leverage.
Hims & Hers Health: What the latest results show
Despite the favorable regulatory tailwinds, investors will scrutinize the company’s underlying performance. Hims & Hers posted robust top-line growth in the past year, aided by intensified consumer demand and expanded channel reach. A fuller look at the latest figures shows: revenue in the double-digit growth band with an expanding subscriber base, and a steady trend in average monthly revenue per subscriber as the product mix matures. The company remains focused on converting subscribers into higher-margin services and products while investing in brand-building and infrastructure to support scale.
On a year-over-year basis, Hims & Hers has delivered meaningful revenue expansion while balancing marketing spend with returns on customer acquisition. In addition to core products, the company’s ongoing efforts to monetize ancillary services are central to its strategy of broadening the value proposition for a health-conscious consumer base.
Progyny Faces a More Cautious 2026, Canaccord Downgrade
Meanwhile, Progyny (PGNY) is navigating a more uncertain growth path as analysts recalibrate expectations for 2026. Canaccord Genuity lowered its price target on Progyny to $19 from $26 while maintaining a Hold rating, citing a slower growth runway and an uncertain macro backdrop for fertility benefits programs despite solid results in the prior year.
Canaccord’s downgrade underscores questions about the pace of adoption for fertility benefits and potential payer mix shifts that could temper revenue expansion. The firm noted that although Progyny delivered record EBITDA in the latest period, the back half of 2025 into 2026 could see a moderation in revenue growth pending policy and corporate benefit decisions across employer-sponsored plans.
Analysts cited a more cautious 2026 outlook for Progyny, estimating revenue growth in the low-to-mid single digits, with a path to profitability contingent on operational efficiency and payer negotiations. The takeaway for investors is a steady, but slower, growth trajectory relative to 2025’s robust 10.4% increase.
Novo Nordisk Deal and the GLP-1 Landscape
The Novo Nordisk distribution agreement that surrounds Hims & Hers remains a pivotal driver of investor sentiment. The deal is viewed as reducing regulatory and legal friction that previously weighed on the stock, while also potentially widening access to GLP-1 therapies through a trusted, consumer-facing health platform. The broader GLP-1 landscape has been a focal point for clinicians, payers, and investors as dialogue around pricing, access, and long-term demand intensifies.
Industry observers say the truce around GLP-1-related partnerships could set a clearer path for players like Hims & Hers to scale in a regulated environment. However, they caution that the market remains sensitive to policy shifts, payer coverage decisions, and competition from other digital-first or traditional care providers expanding into fertility, sexual health, and metabolic wellness.
Market Reaction and What to Watch Next
Trading in Hims & Hers has responded positively to the Barclays note, with shares showing resilience in an otherwise selective market for health tech and consumer-oriented healthcare names. Investors will be watching for any further disclosures about distribution agreements, cross-selling opportunities, and the pace of subscriber growth in the coming quarters.
Progyny’s stock has been trading with elevated sensitivity to 2026 guidance. While the company has repeatedly stressed its positive long-term trajectory, the Canaccord downgrade highlights the need for near-term catalysts—such as payer integrations or employer-partner initiatives—that could support a stronger revenue path in a still-challenging affordability environment.
Key Data Snapshot
- Hims & Hers Health: full-year revenue around $2.35 billion, up roughly 59% year over year
- Subscriber base: surpassing 2.5 million
- Monthly revenue per subscriber: about $83
- Progyny: full-year 2025 revenue approximately $1.289 billion, up 10.4% YoY
- Progyny: adjusted EBITDA around $222.09 million, debt-free
- 2026 guidance: Progyny projected revenue growth of 5%–9% vs 10.4% in 2025
- Target shifts: Barclays lifts Hims & Hers target to $29 from $25
- Canaccord target on Progyny cut to $19 from $26, rating Hold
As markets weigh the implications of the Novo deal and the evolving GLP-1 situation, investors are likely to focus on cash flow, patient access, and the durability of growth for Hims & Hers versus the more modest trajectory for Progyny. The coming quarters will reveal how much of the upside priced in the Barretts of these names translates into real earnings power and sustainable returns for shareholders.
Bottom Line
The headline takeaway is clear: the Novo Nordisk distribution agreement has shifted the risk profile for Hims & Hers, enabling a more constructive growth narrative and a higher price target from Barclays. At the same time, Progyny faces a tempered 2026 outlook as Canaccord steps back from an earlier optimism. For investors, the key question remains whether Hims & Hers can convert expanded access into meaningful profitability while Progyny builds a steadier, though slower, growth runway in a volatile benefits landscape.
Discussion